{"type":"trials","record":{"id":87204,"source_id":"isrctn","external_id":"ISRCTN81615611","title":"The safety and efficacy of posterior juxta-scleral (40 mg) or intra-vitreal (4 mg) triamcinolone acetonide, in addition to verteporfin photodynamic therapy for choroidal neovascularization (CNV), in age-related macular degeneration (AMD): a randomised controlled trial - STUDY STOPPED","brief_summary":"To compare the effectiveness of (a) intra-vitreal and (b) posterior juxta-scleral triamcinolone acetonide as an adjunt to verteporfin photodynamic therapy for CNV secondary to AMD with (c) verteporfin photodynamic therapy alone.","overall_status":"Stopped","phases":[],"study_type":"Interventional","sponsor":"The Newcastle upon Tyne Hospitals NHS Trust (UK)","enrollment":400,"countries":["United Kingdom","England"],"start_date":"2005-10-01","completion_date":"2007-10-01","last_update_date":"2007-09-07","source_url":"https://www.isrctn.com/ISRCTN81615611","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Stopped. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Senior","comparator":null,"attribution":"Source: ISRCTN ISRCTN81615611; retrieved 2026-09-25","interventions":["Triamcinolone acetonide","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Number of patients losing more than 15 letters (3 lines) of visual acuity (ETDRS logMAR chart at 2m) at 1 year.","1. Change in lesion size at one year 2. Number of re-treatments required in one year 3. Incidence of serious complicati…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Choroidal neovascularization (CNV) secondary to Age-related macular degeneration (AMD)","1. Posterior juxta-scleral (40 mg) triamcinolone acetonide + verteporfin photodynamic therapy 2. Intra-vitreal (4 mg) t…","Triamcinolone acetonide","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn81615611","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2005-10-01 to 2007-10-01","comparator":null,"confidence":"structured-source","population":"All · Senior","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.602Z","intervention":["Triamcinolone acetonide","Drug"],"participants":400,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of patients losing more than 15 letters (3 lines) of visual acuity (ETDRS logMAR chart at 2m) at 1 year.","1. Change in lesion size at one year 2. Number of re-treatments required in one year 3. Incidence of serious complicati…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87204","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}